In conclusion, our study demonstrated that CASC15 contributed to melanoma progression partially by EZH2-medicated silence of PDCD4 expression, illuminating the promising prospect of CASC15 as a potential target and therapeutic application for melanoma patients. Here, CASC15 is linked to melanoma.